首页> 外文OA文献 >Analysis of IgV gene mutations in B cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery
【2h】

Analysis of IgV gene mutations in B cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery

机译:根据抗原驱动的选择分析B细胞慢性淋巴细胞性白血病中的IgV基因突变,可确定具有不同预后和使用典型体细胞超突变机制的亚组

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cases of B-cell chronic lymphocytic leukaemia (B-CLL) with mutated (M) IgV(H) genes have a better prognosis than unmutated (UM) cases. We analysed the IgV(H) mutational status of B-CLL according to the features of a canonical somatic hypermutation (SHM) process, correlating this data with survival. In a series of 141 B-CLLs, 124 cases were examined for IgV(H) gene per cent mutations and skewing of replacement/silent mutations in the framework/complementarity-determining regions as evidence of antigen-driven selection; this identified three B-CLL subsets: significantly mutated (sM), with evidence of antigen-driven selection, not significantly mutated (nsM) and UM, without such evidence and IgV(H) gene per cent mutations above or below the 2% cut-off. sM B-CLL patients had longer survival within the good prognosis subgroup that had more than 2% mutations of IgV(H) genes. sM, nsM and UM B-CLL were also characterized for the biased usage of IgV(H) families, intraclonal IgV(H) gene diversification, preference of mutations to target-specific nucleotides or hotspots, and for the expression of enzymes involved in SHM (translesion DNA polymerase zeta and eta and activation-induced cytidine deaminase). These findings indicate the activation of a canonical SHM process in nsM and sM B-CLLs and underscore the role of the antigen in defining the specific clinical and biological features of B-CLL.
机译:带有(M)IgV(H)基因突变的B细胞慢性淋巴细胞性白血病(B-CLL)病例比未突变(UM)病例预后更好。我们根据规范的体细胞高突变(SHM)过程的特征分析了B-CLL的IgV(H)突变状态,并将该数据与生存率相关联。在一系列的141个B-CLL中,检查了124个病例的IgV(H)基因百分比突变以及框架/互补决定区中置换/沉默突变的倾斜,以此作为抗原驱动选择的证据。这确定了三个B-CLL子集:显着突变(sM),有抗原驱动选择的证据,没有显着突变(nsM)和UM,没有此类证据和IgV(H)基因突变百分比高于或低于2% -关。 sM B-CLL患者在预后良好的亚组中具有更长的生存期,该亚组的IgV(H)基因突变超过2%。 sM,nsM和UM B-CLL还针对IgV(H)家族的偏向使用,克隆内IgV(H)基因多样化,突变对靶标特异性核苷酸或热点的偏爱以及SHM中涉及的酶的表达进行了表征(转染DNA聚合酶ζ和eta和激活诱导的胞苷脱氨酶)。这些发现表明在nsM和sM B-CLL中规范性SHM过程的激活,并强调了抗原在定义B-CLL的特定临床和生物学特征中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号